Showing results (171-180 of 313) with videos related to

Sort By:
Pageof 32
Blood|October 7, 2010
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapyFarhad Ravandi, Jorge Cortes, Stefan Faderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Phase I study of bortezomib in refractory or relapsed acute leukemiasJorge Cortes, Deborah Thomas, Charles Koller, et al.
Cancer|January 28, 2004
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapyGloria N Mattiuzzi, Hagop Kantarjian, Stefan Faderl, et al.
Blood|December 9, 2008
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapyElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Blood|July 30, 2010
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Farhad Ravandi, Susan O'Brien, et al.
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Cancer|October 25, 2011
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicinFarhad Ravandi, Keyur Patel, Rajyalakshmi Luthra, et al.
Leukemia & Lymphoma|May 6, 2014
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz, H Jean Khoury, Elias Jabbour, et al.
Pageof 32